Search clinical trials for: borderline resectable

Total 1676 results

Emory University
National Cancer Institute (NCI)

Not yet recruiting

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Ductal Adenocarcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer (undetermined)

Borderline Resectable Pancreatic Cancer
Amsterdam UMC, location VUmc
Maastricht University Medical Center; Erasmus Medical Center; St. Antonius Hospital

Not yet recruiting

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) (PREOPANC-5)

Borderline Resectable Pancreatic Cancer
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Borderline Resectable Pancreatic Cancer

China
Roswell Park Cancer Institute

Recruiting

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

United States
Fujian Medical University Union Hospital

Recruiting

Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Pancreatic Neoplasms

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

Pancreatic Cancer
University of Alabama at Birmingham

Not yet recruiting

DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

Borderline-resectable Pancreatic Cancer

United States
University of Colorado, Denver
Tvardi Therapeutics, Incorporated

Recruiting

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Georgetown University
AstraZeneca

Recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
Peking Union Medical College Hospital

Recruiting

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer (MAP-03)

Pancreatic Cancer | Locally Advanced

China
Varian, a Siemens Healthineers Company
Washington University School of Medicine

Recruiting

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach (ARTIA-Pancreas)

Pancreatic Cancer

United States
Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
Hospital del Mar

Not yet recruiting

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline (PaNLoCat)

Chemotherapy Effect | Pancreas Cancer

Spain
BUSQUETS, JULI

Not yet recruiting

Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy (PF-BARNA)

Carcinoma, Pancreatic Ductal
Umeå University
Karolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaborators

Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer (SQUARE)

Quality of Life | Surgery | Pancreas Adenocarcinoma | Chemotherapy Effect | Pancreas Cancer | Pancreas Neoplasm | Pancreas Disease | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

Sweden
University Hospital, Ghent

Recruiting

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy (PeRFormanCe Trial) (PeRFormanCe)

Pancreatic Cancer

Belgium
City of Hope Medical Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC

Locally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma

United States
Erasme University Hospital
Jules Bordet Institute; University Hospital St Luc, Brussels; Belgian Group of...

Recruiting

Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma (STEREOPAC)

Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Pancreatic Neoplasm

Belgium
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Capital Health System, Inc

Recruiting

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
Lawson Health Research Institute
London Health Sciences Foundation

Not yet recruiting

Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma (ANSR-PDAC)

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
EBG MedAustron GmbH
Landesklinkum Wiener Neustadt

Recruiting

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (PARC)

Pancreatic Cancer | Proton Therapy

Austria
Fudan University
West China Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Zhejiang... and other collaborators

Recruiting

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Borderline Resectable Pancreatic Cancer

China
Associazione Italiana per lo Studio del Pancreas
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente; High Research...

Recruiting

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) (CASSANDRA)

Pancreas Ductal Adenocarcinoma

Italy
Fudan University

Recruiting

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Cancer

China
OHSU Knight Cancer Institute
Oregon Health and Science University

Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8

United States
Fujian Medical University Union Hospital

Recruiting

Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer

Pancreatic Neoplasms

China
University of Utah
National Cancer Institute (NCI)

Recruiting

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER) (SHAPER)

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Locally Advanced Unresectable Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Ductal...

United States
CNAO National Center of Oncological Hadrontherapy
Foundation IRCCS San Matteo Hospital

Recruiting

Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma (PIOPPO)

Pancreas Adenocarcinoma | Resectable Pancreatic Cancer | Cancer of Pancreas

Italy
Changhai Hospital

Recruiting

Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1 (BRPCNCC-1)

Pancreatic Cancer

China
Medical College of Wisconsin

Recruiting

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Benaroya Research Institute

Recruiting

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Pancreatic Adenocarcinoma

United States
CivaTech Oncology

Recruiting

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Pancreatic Cancer

United States
Proton Collaborative Group
University of Florida Health

Recruiting

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

Pancreatic Cancer

United States
Craig L Slingluff, Jr

Recruiting

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

Pancreatic Cancer

United States
Abramson Cancer Center at Penn Medicine

Recruiting

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy | Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

United States
Silenseed Ltd

Recruiting

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer (PROTACT)

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States, Israel
Herlev Hospital

Active, not recruiting

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. (LAPTOP)

Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer

Denmark
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Universita di Verona

Suspended

IORT on Borderline Resectable Pancreatic Cancer (PancFORT)

Borderline Resectable Pancreatic Cancer

Italy
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; NovoCure Ltd.

Active, not recruiting

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Borderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma

United States
Do-Youn Oh
AstraZeneca

Active, not recruiting

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Completed

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Academic Thoracic Oncology Medical Investigators...
University of Colorado, Denver; Celgene Corporation; Criterium, Inc.

Active, not recruiting

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Ductal Adenocarcinoma

United States

Search clinical trials for: borderline resectable

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations